More than 40,000 doctors and healthcare professionals are expected this weekend in Chicago for the world cancer meeting, ASCO (1).
The 4,700 studies that will be presented will open up avenues for the prevention, treatment and monitoring of cancers for years to come. The 2015 edition highlighted the revolution in immunotherapies, this year’s vintage should be less exceptional.
But the public enemy has not changed. With 45,000 new cases each year in France, lung cancer remains the killer of men the most (21,000 deaths). “Among women, notes The Parisianit follows breast cancer and kills 9,500 people every year”.
And, in this area, the daily has spotted the study which should make “a big buzz” at ASCO 2016. It will be presented next Monday by a French team from the Jean-Bernard institute in Le Mans (Sarthe), conducted by Dr. Fabrice Denis. It is “a digital application aimed at improving the personalized, remote follow-up of patients suffering from this disease”, writes the journalist. An essential tool for adapting treatment as quickly as possible in the event of a complication or recurrence of the disease.
The app, available on tablet or smartphone, allows the patient to describe the evolution of his disease in detail every week. Stored on a secure server, the medical data will then be analyzed by software. In the event of a clinical anomaly, the doctor is alerted and the patient invited to consult. A procedure much faster than that in force with monitoring by scanner every 3 or 6 months.
But will it be as effective? If some specialists interviewed by the newspaper are still skeptical, Dr. Fabrice Denis argues that, as with a drug, a clinical study will be conducted to assess the relevance of this concept.
(1) American Society of Clinical Oncology
First publication: June 03, 2016
